Hydreight Technologies: A Strong Quarter With Some Yellow Flags (Rating Downgrade)

Hydreight Technologies is downgraded from Strong Buy to Buy after Q2 2026 revealed slowing sequential growth and margin pressure. NURS Q2 revenue grew 12% QoQ to $28M, missing expectations and raising concerns about achieving FY2026's $150M guidance. Gross margin fell to 19.4% due to increased pharmacy sales and pricing concessions, while cash burn remained elevated amid rapid expansion. Despite near-term caution, my valuation still shows nearly 100% upside by 2028, providing margin of safety at current levels.

Hydreight Technologies delivered another record quarter, but Q2 also exposed some cracks in the growth story, with sequential revenue growth slowing to 12% and margins weakening while cash burn was high.